Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Entolimod
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase III
Recipient : Scorpius Holdings
Deal Size : Undisclosed
Deal Type : Agreement
Tivic Signs GMP Validation Pact with Scorpius Ahead of FDA Submission
Details : Under the agreement, Scorpius will be the US manufacturer for Entolimod. It plans to utilize its technical expertise to validate the manufacturing process for Tivic’s lead candidate, Entolimod.
Product Name : STAT-600
Product Type : Protein
Upfront Cash : Undisclosed
May 14, 2025
Lead Product(s) : Entolimod
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase III
Recipient : Scorpius Holdings
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Entolimod
Therapeutic Area : Hematology
Study Phase : Phase III
Recipient : Statera Biopharma
Deal Size : $1.5 million
Deal Type : Licensing Agreement
Tivic Expands TLR5 Entolimod License to Treat Neutropenia
Details : Under the licensing agreement, Tivic will obtains the rights of Entolimod TMC (entolimod). Iti s an being evaluated for treating for individuals with Neutropenia.
Product Name : STAT-600
Product Type : Protein
Upfront Cash : $1.5 million
April 15, 2025
Lead Product(s) : Entolimod
Therapeutic Area : Hematology
Highest Development Status : Phase III
Recipient : Statera Biopharma
Deal Size : $1.5 million
Deal Type : Licensing Agreement